John Brownlee's team investigates Purdue and secures a federal plea agreement

John Brownlee’s investigation of Purdue turned a dispersed record of OxyContin-related warnings, deaths, and litigation into a federal prosecution, ending in a 2007 plea agreement that acknowledged fraudulent marketing but imposed narrower charges than his team had sought. The case’s central tension was between the scale of the evidence and the limits of the settlement: prosecutors secured corporate and executive guilty pleas and hundreds of millions of dollars in fines, but not the broader felony indictment or billion-dollar corporate penalty initially contemplated.

The prosecutor and the accumulating record

In 2003, while legal proceedings had still failed to prove that OxyContin’s makers had broken the law, Brownlee began working secretly on a federal case against Purdue. A former paratrooper and Army Reserve JAG Corps captain, he was a thirty-six-year-old U.S. attorney with political aspirations and a taste for high-stakes prosecution. His public style was conspicuous: he carried a portable podium for press conferences. That visibility accompanied a reputation for aggressive tactics, shaped in part by an earlier trial loss in a wrongful-death case against Roanoke pain specialist Dr. Cecil Knox. Brownlee’s case against Purdue would depend not on drama alone but on building a documentary record capable of sustaining a difficult prosecution.

An important stream of leads came through Gregg Wood, a fraud investigator in Brownlee’s office. Since the epidemic’s early years, Wood had circulated regular email compilations of OxyContin news and overdose statistics to law-enforcement agents, prosecutors, and others who might identify local developments. Art Van Zee called these updates the Wood Reports. Brownlee also studied the footnotes in Barry Meier’s book about OxyContin, while Wood communicated with Van Zee and parents involved in Relatives Against Purdue Pharma. Together, these channels connected public reporting, local experience, and prosecutorial investigation without making any single source carry the whole case.

The material accumulated in several forms. Files from Fayne McCauley’s litigation, including sales-representative call notes and depositions, were incorporated into the federal team’s evidence. Brownlee’s office was secretly logging millions of records in spreadsheets; the Wood Reports appeared four or five times a week, and one employee was assigned solely to catalog documents. The accumulating archive strengthened Brownlee’s view that Purdue had knowingly concealed OxyContin’s addictiveness. When news of a federal grand-jury investigation broke in 2005, the effort had already become a large-scale evidence operation, not simply a response to the latest public controversy.

Building and escalating the case

Brownlee expanded the prosecution beyond his own office, bringing in prosecutors from neighboring jurisdictions and appointing Randy Ramseyer and Rick Mountcastle to lead the Purdue investigation. They were career government lawyers based in Abingdon, closer to the coalfields than Brownlee’s Roanoke office. Their work gave the case an institutional structure suited to the volume of records and the seriousness of the allegations. By the fall of 2006, a federal prosecutors’ memo indicated that the evidence might support charges not only for misbranding OxyContin but also for mail fraud, wire fraud, and money laundering against the company and its top executives.

The prosecution developed against a record that raised questions about what was known about the drug’s risks and how its marketing was overseen. The 1995 application reviewed by Curtis Wright described how crushing the tablets could release the drug immediately, recorded withdrawal symptoms in clinical-trial patients, and stated that 68 percent of the oxycodone in one crushed pill could be recovered for injection. Purdue later said it had not known about abuse problems until February 2000. Wright’s approval summary also urged restraint in competitive promotion; he went on to work as a consultant for Purdue two years later. These details form part of the wider regulatory and promotional context surrounding the prosecution; the available account does not establish that Brownlee’s team relied on each of them as evidence in its case.

Negotiations and pressure

The prospect of a broader indictment sharpened negotiations. Purdue initially offered $10 million, while the government’s initial proposal was $1 billion. The possible charges against executives were also narrowed as the proposed settlement moved through the United States Department of Justice. An observer connected to the case said that Purdue’s representatives, including Rudy Giuliani, lobbied hard to keep the executives from facing felony charges. The final terms would reflect both the prosecutors’ accumulated evidence and the institutional negotiations that constrained what charges survived.

Pressure had surfaced before the final bargaining. In 2005, Purdue lawyers complained to Deputy Attorney General James Comey about Brownlee’s investigative tactics, and Comey raised concerns with him. Brownlee drove to Washington to explain his strategy and was told to return to Virginia and continue the case. The most acute intervention came in October 2006, on the night before the plea agreement was due to expire. At the request of a Purdue lawyer, a senior Justice Department official telephoned Brownlee at home to urge an extension. Brownlee did not extend the deadline. Purdue accepted the agreement that night rather than risk more serious charges or a jury trial in Southwest Virginia, where OxyContin’s toll had become widely known.

Eight days after Purdue accepted the deal, Brownlee saw his name on a list of U.S. attorneys to be fired, along with four others. He was not ultimately fired, but the episode added to criticism of Attorney General Alberto Gonzales over possible efforts to influence the work of U.S. attorneys’ offices. The account also identifies Mary Jo White, a former Manhattan U.S. attorney who represented Purdue, as the lawyer who pressed for more time in the call to a Justice Department official. Brownlee later addressed the attempted influence in a Senate hearing about the case.

The 2007 agreement

In May 2007, Brownlee announced the settlement at a downtown Roanoke office building. Purdue would pay $600 million to resolve federal criminal and civil misbranding charges and admit that, for six years, it had fraudulently marketed OxyContin as less prone to abuse and as causing fewer narcotic side effects than immediate-release versions of the drug. Purdue Frederick, a Purdue-owned holding company, pleaded guilty to a felony misbranding charge. The executives Paul Goldenheim, Michael Friedman, and Howard Udell pleaded guilty to misdemeanor misbranding charges; $34.5 million in fines on their behalf would be paid by the firm.

The pleas carefully limited what the executives admitted. They did not stipulate that they had direct knowledge of the misbranding, instead accepting language that the court could consider the stated facts in support of their guilty pleas. The result was substantially narrower than the charges Ramseyer and Mountcastle had originally threatened: the corporate felony remained, but the executives faced misdemeanors rather than the proposed felony charges, and the settlement did not include the billion-dollar corporate penalty prosecutors had first sought. The fines against Purdue and its executives amounted to about 90 percent of the company’s profits from OxyContin’s 1996 launch through 2001, when Purdue removed insert language claiming that the timed-release mechanism could reduce a drug’s abuse liability. The penalty was the eleventh largest paid by a pharmaceutical firm in the history of the Department of Justice.

Evidence, accountability, and limits

The press conference made the investigation’s material scale visible. Brownlee presented the settlement alongside Gregg Wood, Ramseyer, Mountcastle, and others on the prosecution team. Nearby stood columns of boxes, four to five feet high, drawn from roughly two thousand cardboard containers filled with documents, depositions, and data. The archive served as a concrete counterweight to the company’s earlier legal victories and to the difficulty of proving wrongdoing in court.

The agreement also created a formal occasion for people harmed by OxyContin. A sentencing hearing was planned for July in Abingdon, where grieving parents, including advocates such as Art Van Zee and Barbara Van Rooyan, were invited to speak on the record about the drug’s effects. The executives were not to serve jail time under the plea agreement, although the judge would determine the exact terms of probation and community service at their court appearance. The settlement therefore offered a measure of public acknowledgment and substantial financial punishment, while leaving a marked gap between the prosecution’s initial ambitions and the final legal admissions. Its outcome illustrates the difference between assembling evidence strong enough to force a corporate plea and securing the full range of charges prosecutors believe that evidence could support.